V.M. Katoch, former Director General of the Indian Council of Medical Research (ICMR) and ex-Health Research Secretary, praised India’s launch of the Human Papillomavirus (HPV) vaccination nationwide. Describing it as a pivotal moment in India’s public health journey, he emphasized the significance of this step in combating cervical cancer, a major cause of cancer-related deaths among Indian women. Katoch highlighted the effectiveness of the HPV vaccine in preventing HPV infection and reducing cervical cancer cases globally.
The inclusion of the HPV vaccine in the national immunization program is seen as a crucial move to protect women, especially the economically vulnerable, who were previously unable to access the vaccine through private healthcare facilities. By making the vaccine more accessible, the program aims to shield those at high risk and curb the transmission of HPV in the community. Katoch expressed optimism that sustained implementation of the vaccination program could lead to the eradication of cervical cancer as a public health threat in India.
India had approved the HPV vaccine nearly two decades ago, but its availability was limited to those who could afford it privately. With its integration into the national program, the vaccine is expected to reach a broader population, particularly benefiting girls from economically weaker backgrounds. The move is anticipated to not only safeguard young girls from HPV before exposure but also contribute to reducing the overall burden of cervical cancer in the country.
